1. [Progress in Clinical Researches of PD-1/PD-L1 Checkpoint Inhibitor for Non-small Cell Lung Cancer].
- Author
-
Wu S, Hu C, Wu F, Wu Y, and Liu P
- Subjects
- Antineoplastic Agents pharmacology, Antineoplastic Agents therapeutic use, B7-H1 Antigen metabolism, Carcinoma, Non-Small-Cell Lung pathology, Humans, Lung Neoplasms pathology, Programmed Cell Death 1 Receptor metabolism, B7-H1 Antigen antagonists & inhibitors, Carcinoma, Non-Small-Cell Lung drug therapy, Carcinoma, Non-Small-Cell Lung metabolism, Lung Neoplasms drug therapy, Lung Neoplasms metabolism, Molecular Targeted Therapy methods, Programmed Cell Death 1 Receptor antagonists & inhibitors
- Abstract
Non-small cell lung cancer (NSCLC) is the most common pathological type of lung cancer. In recent years, immunotherapy has developed rapidly. Immune checkpoint inhibitors, especially programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors have made a breakthrough in the treatment of NSCLC and changed the treatment pattern for NSCLC. Immunological checkpoint inhibitors targeting PD-1/PD-L1 are beneficial to patients, both in the first-line and second-line treatment of advanced NSCLC, in the adjuvant treatment of locally-advanced NSCLC, and in the neoadjuvant therapy of early NSCLC, which show an important role in the comprehensive treatment of NSCLC. This article reviews the clinical research progress of immunological checkpoint inhibitors targeting PD-1/PD-L1 in NSCLC. .
- Published
- 2019
- Full Text
- View/download PDF